Updated: 07 Jan 2001
1 Tbl. enth.: Lachesis D12 10 mg, Cimicifuga D5 10 mg, Sepia D5 10 mg, Lilium tigrinum D5 10 mg.
The Lysosomal Acid Lipase (LAL) Deficiency Knowledge Centre contains a range of accurate, informative clinical content for healthcare professionals. The disease awareness section presents epidemiology, pathophysiology and diagnosis information, among others. The treatment section details the drug characteristics, safety and efficacy of sebelipase alfa – the first and only licenced treatment for LAL deficiency. The resources section contains further clinical content including a video channel presenting expert opinions on diagnostic approach and current prognosis.
Developed by EPG Health Media (Europe) Ltd for epgonline.org, in collaboration and with content provided by Alexion Pharma GmbH
In this EACCME-accredited online CME activity Individual Patient Management in Type 1 Childhood Diabetes, healthcare professionals will learn how to assess the psychosocial wellbeing of young patients with type 1 diabetes.
Upon successful completion of this activity, healthcare professionals (such as endocrinologists, paediatricians, paediatric endocrinologists, diabetes specialists, specialist nurses, primary care physicians) will be awarded 1 European CME credit (ECMEC).
See disease awareness facts and stats, information on sebelipase alfa (the first and only licensed treatment for LAL-D) and resources section, including expert video channel…